Rhythm Pharmaceuticals (RYTM) Liabilities and Shareholders Equity (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $442.3 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 14.39% year-over-year to $442.3 million in Q1 2026; TTM through Mar 2026 was $1.8 billion, a 18.22% increase from a year earlier, with the FY2025 full-year figure at $480.2 million, up 22.41% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $442.3 million, down from $480.2 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RYTM reached as high as $506.9 million in Q3 2025 and fell as low as $258.7 million in Q1 2024.
• Historically, Liabilities and Shareholders Equity has averaged $368.4 million across 5 years, with a median of $372.7 million in 2025.
• Across the five-year window, Liabilities and Shareholders Equity tumbled 32.54% in 2022 and jumped 49.5% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $382.5 million in 2022, then dropped by 13.0% to $332.7 million in 2023, then climbed by 17.89% to $392.3 million in 2024, then increased by 22.41% to $480.2 million in 2025, then decreased by 7.89% to $442.3 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $442.3 million in Q1 2026, $480.2 million in Q4 2025, and $506.9 million in Q3 2025.